Having joined Ovid Therapeutics, Inc. in 2020, Julia Tsai led the development of soticlestat, a treatment for developmental and...
Ovid Therapeutics: Seeking Innovation In Epilepsy Treatment
An Interview With 2023 Rising Leader Julia Tsai
Rising Leader Julia Tsai wants to see Ovid Therapeutics become a market leading epilepsy company that listens to the needs of patients and develops innovative drugs to treat a spectrum of epileptic indications and symptoms.
